TY - JOUR
T1 - Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis
AU - Panizzutti, Bruna
AU - Skvarc, David
AU - Lin, Sylvia
AU - Croce, Sarah
AU - Meehan, Alcy
AU - Bortolasci, Chiara Cristina
AU - Marx, Wolfgang
AU - Walker, Adam J.
AU - Hasebe, Kyoko
AU - Kavanagh, Bianca E.
AU - Morris, Margaret J.
AU - Mohebbi, Mohammadreza
AU - Turner, Alyna
AU - Gray, Laura
AU - Berk, Lesley
AU - Walder, Ken
AU - Berk, Michael
AU - Dean, Olivia M.
N1 - Funding Information:
A.J.W. gratefully acknowledges support from a Trisno Family Fellowship funded in part by an NHMRC CRE (1153607). M.B. is supported by an NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator grant (1156072 and 2017131). W.M. is currently funded by an NHMRC Investigator Grant (#2008971) and a Multiple Sclerosis Research Australia early-career fellowship.
Funding Information:
O.M.D. has received grant/research support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC, and the Australasian Society for Bipolar and Depressive Disorders (ASBDD)/Servier. O.M.D. has also received in-kind support from BioMedica Nutraceuticals, NutritionCare, and Bioceuticals. W.M. has previously received funding from the Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University. W.M. has received industry funding and/or has attended events funded by Cobram Estate Pty. Ltd. and Bega Dairy and Drinks Pty Ltd. W.M. has received travel funding from the Nutrition Society of Australia. W.M. has received consultancy funding from Nutrition Research Australia and ParachuteBH. W.M. has received speakers’ honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/3/9
Y1 - 2023/3/9
N2 - Minocycline has anti-inflammatory, antioxidant, and anti-apoptotic properties that explain the renewed interest in its use as an adjunctive treatment for psychiatric and neurological conditions. Following the completion of several new clinical trials using minocycline, we proposed an up-to-date systematic review and meta-analysis of the data available. The PICO (patient/population, intervention, comparison and outcomes) framework was used to search 5 databases aiming to identify randomized controlled trials that used minocycline as an adjunctive treatment for psychiatric and neurological conditions. Search results, data extraction, and risk of bias were performed by two independent authors for each publication. Quantitative meta-analysis was performed using RevMan software. Literature search and review resulted in 32 studies being included in this review: 10 in schizophrenia, 3 studies in depression, and 7 in stroke, with the benefit of minocycline being used in some of the core symptoms evaluated; 2 in bipolar disorder and 2 in substance use, without demonstrating a benefit for using minocycline; 1 in obsessive-compulsive disorder, 2 in brain and spinal injuries, 2 in amyotrophic lateral sclerosis, 1 in Alzheimer’s disease, 1 in multiple systems atrophy, and 1 in pain, with mixes results. For most of the conditions included in this review the data is still limited and difficult to interpret, warranting more well-designed and powered studies. On the other hand, the studies available for schizophrenia seem to suggest an overall benefit favoring the use of minocycline as an adjunctive treatment.
AB - Minocycline has anti-inflammatory, antioxidant, and anti-apoptotic properties that explain the renewed interest in its use as an adjunctive treatment for psychiatric and neurological conditions. Following the completion of several new clinical trials using minocycline, we proposed an up-to-date systematic review and meta-analysis of the data available. The PICO (patient/population, intervention, comparison and outcomes) framework was used to search 5 databases aiming to identify randomized controlled trials that used minocycline as an adjunctive treatment for psychiatric and neurological conditions. Search results, data extraction, and risk of bias were performed by two independent authors for each publication. Quantitative meta-analysis was performed using RevMan software. Literature search and review resulted in 32 studies being included in this review: 10 in schizophrenia, 3 studies in depression, and 7 in stroke, with the benefit of minocycline being used in some of the core symptoms evaluated; 2 in bipolar disorder and 2 in substance use, without demonstrating a benefit for using minocycline; 1 in obsessive-compulsive disorder, 2 in brain and spinal injuries, 2 in amyotrophic lateral sclerosis, 1 in Alzheimer’s disease, 1 in multiple systems atrophy, and 1 in pain, with mixes results. For most of the conditions included in this review the data is still limited and difficult to interpret, warranting more well-designed and powered studies. On the other hand, the studies available for schizophrenia seem to suggest an overall benefit favoring the use of minocycline as an adjunctive treatment.
UR - http://www.scopus.com/inward/record.url?scp=85151109671&partnerID=8YFLogxK
U2 - 10.3390/ijms24065250
DO - 10.3390/ijms24065250
M3 - Review article
C2 - 36982324
AN - SCOPUS:85151109671
SN - 1661-6596
VL - 24
SP - 1
EP - 28
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 6
M1 - 5250
ER -